PPPrathima Prodduturi

Prathima Prodduturi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Prathima Prodduturi has a total of 1 co-authors. Here are the top co-authors by number of shared publications:

  • Philip J Bierman

    University of Nebraska Medical Center, Division of Hematology and Oncology, Omaha, Ne, USA 68198–7680

    1 shared publication

Latest Publications

  • Open Access

    Current and Emerging Pharmacotherapies for Primary CNS Lymphoma

    by Prathima Prodduturi, Philip J Bierman

    Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.